GB201220901D0 - CD44v6-derived peptides for treating pancreatic cancer - Google Patents

CD44v6-derived peptides for treating pancreatic cancer

Info

Publication number
GB201220901D0
GB201220901D0 GBGB1220901.1A GB201220901A GB201220901D0 GB 201220901 D0 GB201220901 D0 GB 201220901D0 GB 201220901 A GB201220901 A GB 201220901A GB 201220901 D0 GB201220901 D0 GB 201220901D0
Authority
GB
United Kingdom
Prior art keywords
cd44v6
pancreatic cancer
derived peptides
treating pancreatic
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1220901.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karlsruher Institut für Technologie
Original Assignee
Karlsruher Institut für Technologie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karlsruher Institut für Technologie filed Critical Karlsruher Institut für Technologie
Priority to GBGB1220901.1A priority Critical patent/GB201220901D0/en
Publication of GB201220901D0 publication Critical patent/GB201220901D0/en
Priority to US14/407,244 priority patent/US9586993B2/en
Priority to EP13794910.3A priority patent/EP2922561A1/en
Priority to JP2015543431A priority patent/JP2016501857A/ja
Priority to PCT/EP2013/074401 priority patent/WO2014079940A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
GBGB1220901.1A 2012-11-21 2012-11-21 CD44v6-derived peptides for treating pancreatic cancer Ceased GB201220901D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB1220901.1A GB201220901D0 (en) 2012-11-21 2012-11-21 CD44v6-derived peptides for treating pancreatic cancer
US14/407,244 US9586993B2 (en) 2012-11-21 2013-11-21 CD44v6-derived peptides for treating pancreatic cancer
EP13794910.3A EP2922561A1 (en) 2012-11-21 2013-11-21 Cd44v6-derived peptides for treating pancreatic cancer
JP2015543431A JP2016501857A (ja) 2012-11-21 2013-11-21 膵癌を処置するためのｃｄ４４ｖ６由来ペプチド
PCT/EP2013/074401 WO2014079940A1 (en) 2012-11-21 2013-11-21 Cd44v6-derived peptides for treating pancreatic cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1220901.1A GB201220901D0 (en) 2012-11-21 2012-11-21 CD44v6-derived peptides for treating pancreatic cancer

Publications (1)

Publication Number Publication Date
GB201220901D0 true GB201220901D0 (en) 2013-01-02

Family

ID=47521471

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1220901.1A Ceased GB201220901D0 (en) 2012-11-21 2012-11-21 CD44v6-derived peptides for treating pancreatic cancer

Country Status (5)

Country Link
US (1) US9586993B2 (cg-RX-API-DMAC10.html)
EP (1) EP2922561A1 (cg-RX-API-DMAC10.html)
JP (1) JP2016501857A (cg-RX-API-DMAC10.html)
GB (1) GB201220901D0 (cg-RX-API-DMAC10.html)
WO (1) WO2014079940A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201421647D0 (en) * 2014-12-05 2015-01-21 Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases
EP4464714A1 (en) 2023-05-19 2024-11-20 Karlsruher Institut für Technologie Screening method for cell-repelling peptides

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19540515C1 (de) 1995-10-31 1997-02-06 Boehringer Ingelheim Int Tumortherapie durch adoptiven Transfer CD44v-spezifischer zytotoxischer T-Lymphozyten
GB9901710D0 (en) 1999-01-26 1999-03-17 Prolifix Ltd Peptide inhibitors
EP1258255A1 (en) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
EP1391213A1 (en) * 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
EP1417974A1 (en) 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
WO2005065709A2 (de) * 2003-12-24 2005-07-21 Boehringer Ingelheim International Gmbh Gefriergetrocknete formulierung von antikörperkonjugaten
EP1647556B1 (en) 2004-10-14 2010-05-19 Karlsruher Institut für Technologie Peptidic compounds and derivatives thereof for the treatment of human diseases through inhibition of signaling via growth factors
EP2343551B1 (en) 2006-04-10 2014-05-28 Genentech, Inc. Dishevelled PDZ modulators
PT2193142E (pt) 2007-08-30 2015-04-22 Curedm Group Holdings Llc Composições e procedimentos de utilização de peptídeos pro-ilhota e seus análogos
ATE523204T1 (de) 2009-02-16 2011-09-15 Karlsruher Inst Technologie Cd44v6-peptide als bakterielle infektionsinhibitoren
EP2266593A1 (en) 2009-06-24 2010-12-29 Karlsruher Institut für Technologie Use of CD44v6 in the treatment of ophthalmic diseases
WO2011022335A1 (en) * 2009-08-21 2011-02-24 Mount Sinai School Of Medicine Of New York University Methods of using cd44 fusion proteins to treat cancer
US20120258998A1 (en) 2011-04-05 2012-10-11 Patrick Tan Fusion genes in gastrointestinal cancer

Also Published As

Publication number Publication date
WO2014079940A1 (en) 2014-05-30
US20150166607A1 (en) 2015-06-18
US9586993B2 (en) 2017-03-07
EP2922561A1 (en) 2015-09-30
JP2016501857A (ja) 2016-01-21

Similar Documents

Publication Publication Date Title
IL272206A (en) Combined treatment for cancer
IL267242B (en) Cancer treatment
PL3967315T3 (pl) Akkermansia muciniphila do leczenia nowotworu złośliwego
LT2925888T (lt) Vėžio gydymo kompozicijos ir būdai
ZA201205004B (en) Methods for treating pancreatic cancer
IL228644A0 (en) Cancer treatment methods
HRP20160851T1 (hr) Prediktori za liječenje karcinoma
IL245037B (en) Treatment for pancreatic cancer
ZA201503005B (en) Ingenol-derived compounds useful for treating cancer
IL239031A0 (en) Combined therapy for the treatment of her2-positive cancers
IL238606A0 (en) CD44v6-derivative peptides for the treatment of cancer metastases
SG11201502584XA (en) Peptides and methods for treating cancer
DK2872176T3 (en) Cancer treatment
EP2934500A4 (en) COMBINATION THERAPY AGAINST CANCER
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
ZA201504169B (en) Anti-adam28 antibody for treating cancer
IL232479A0 (en) Combined treatment of ovarian cancer
GB201220891D0 (en) CD44v6-derived peptides for treating breast cancers
GB201222563D0 (en) Cancer treatment
IL239231A0 (en) Combined cancer treatment
AU2012901918A0 (en) Methods for treating cancer

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)